2. Клинические рекомендации. Хроническая обструктивная болезнь легких. Российскоереспираторное общество. 2018. Доступ: http://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf (дата обращения – 15.04.2020).

3. http://grls.rosminzdrav.ru (дата обращения – 15.04.2020).

4. Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterolversus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronicobstructive pulmonary disease: results from two multicenter, blinded, randomized controlled trials.Lancet Respir Med. 2014; 2: 472–86. doi: 10.1016/S2213-2600(14)70065-7.

5. Beeh K.M., Westerman J., Kirsten A.M. et al. The 24-h lung-function profile of oncedaily tiotropiumand olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm PharmacolTher. 2015; 32: 53–59. doi: 10.1016/j.pupt.2015.04.002.

6. Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combinationversus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015; 45: 969–79. doi:10.1183/09031936.00136014.

7. Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary diseaseexacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium(SPARK): a randomized, double-blind, parallelgroup study. Lancet Respir Med 2013; 1: 199–209.doi: 10.1016/S2213-2600(13)70052-3.

8. Broekhuizen B.D., Sachs A.P., Moons K.G. et al. Diagnostic value of oral prednisolone test forchronic obstructive pulmonary disorders. Ann Fam Med. 2011; 9: 104–09. doi: 10.1370/afm.1223.

9. Yang I.A., Clarke M.S., Sim E.H.A., Fong K.M. Inhaled corticosteroids for stable chronic obstructivepulmonary disease. Cochrane Database Syst Rev. 2012; 7: CD002991. doi: 10.1002/14651858.CD002991.

10.Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronicobstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of theWISDOM trial. Lancet Respir Med. 2016; 4(5): 390–98. doi: 10.1016/S2213-2600(16)00100-4.

11.Rojas-Reyes M.X., Garcia Morales O.M., Dennis R.J. et al. Combination inhaled steroid andlong-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone forchronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016; 6: CD008532. doi:10.1002/14651858.

12. Национальные клинические рекомендации. Пульмонология. Российское научноемедицинское общество терапевтов (РНМОТ). Под ред. А.Г. Малявина, А.И. Мартынова.Терапия. 2019; 5 (приложение): 1–152.